Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels
暂无分享,去创建一个
J. Dumont | I. Nestorov | D. Quon | K. Pasi | J. Mahlangu | A. Shapiro | D. Lillicrap | M. Ragni | I. Pabinger | A. Srivastava | G. Pierce | Haiyan Jiang | P. Fogarty | H. Jiang | R. Kulkarni | S. Neelakantan | Shuanglian Li | J. Potts | H. Hanabusa | A. Brennan | S. Kulke | Glenn F Pierce | J. Oldenberg | S. Li | I. Pabinger | G. Pierce | Aoife Brennan | Sarah Kulke
[1] J. Dumont,et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics , 2015, Critical reviews in biotechnology.
[2] I. Nestorov,et al. Population pharmacokinetics of recombinant factor VIII Fc fusion protein , 2015, Clinical pharmacology in drug development.
[3] J. Dumont,et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.
[4] S. Jackson,et al. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.
[5] J. Windyga,et al. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.
[6] C. Kempton,et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. , 2013, Blood.
[7] C. Kempton,et al. Randomized, controlled, parallel‐group trial of routine prophylaxis vs. on‐demand treatment with sucrose‐formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) , 2013, Journal of thrombosis and haemostasis : JTH.
[8] R. Gibbs,et al. Characterizing polymorphisms and allelic diversity of von Willebrand factor gene in the 1000 Genomes , 2013, Journal of thrombosis and haemostasis : JTH.
[9] A. Bitonti,et al. Biochemical and functional characterization of a recombinant monomeric factor VIII–Fc fusion protein , 2013, Journal of thrombosis and haemostasis : JTH.
[10] C. Kempton,et al. Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With rFVIII-FS in Adults With Severe Hemophilia A (SPINART). , 2013 .
[11] G. Allen,et al. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.
[12] A. Bitonti,et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. , 2012, Blood.
[13] J. Dumont,et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. , 2012, Blood.
[14] L. Valentino,et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.
[15] G. Spotts,et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. , 2012, Blood.
[16] P. Fogarty,et al. Biological rationale for new drugs in the bleeding disorders pipeline. , 2011, Hematology. American Society of Hematology. Education Program.
[17] Kathleen A. Johnson,et al. Costs of care in hemophilia and possible implications of health care reform. , 2011, Hematology. American Society of Hematology. Education Program.
[18] P. D. de Groot,et al. Up-regulation of platelet activation in hemophilia A , 2011, Haematologica.
[19] M. Morfini,et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.
[20] D. Lillicrap. Improvements in factor concentrates , 2010, Current opinion in hematology.
[21] S. Björkman. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[22] J. O’Donnell,et al. Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.
[23] P. Mannucci,et al. Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.
[24] J. Astermark,et al. Break‐through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.
[25] Mats O. Karlsson,et al. Likelihood based approaches to handling data below the quantification limit using NONMEM VI , 2008, Journal of Pharmacokinetics and Pharmacodynamics.
[26] A. Bertomoro,et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. , 2008, Blood.
[27] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[28] P. Lenting,et al. Clearance mechanisms of von Willebrand factor and factor VIII , 2007, Journal of thrombosis and haemostasis : JTH.
[29] Katsunori Yoshida,et al. Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor β signaling, promoting cirrhosis and hepatocellular carcinoma , 2007, Hepatology.
[30] R. Boulieu,et al. A Limited Sampling Strategy for Estimating Individual Pharmacokinetic Parameters of Coagulation Factor VIII in Patients With Hemophilia A , 2007, Therapeutic drug monitoring.
[31] H. Stass. Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophilia , 2006 .
[32] J. Maahs,et al. Practice patterns in haemophilia A therapy – global progress towards optimal care , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.
[33] J. Korth-Bradley,et al. Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.
[34] P. Mannucci,et al. Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods , 2005, Journal of thrombosis and haemostasis : JTH.
[35] D. Globe,et al. Utilization of care in haemophilia: a resource‐based method for cost analysis from the Haemophilia Utilization Group Study (HUGS) , 2004, Haemophilia : the official journal of the World Federation of Hemophilia.
[36] S. Björkman. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.
[37] M. Manco‐Johnson,et al. Barriers to compliance with prophylaxis therapy in haemophilia , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.
[38] E G Tuddenham,et al. The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.
[39] C. Denis,et al. Defect in regulated secretion of P-selectin affects leukocyte recruitment in von Willebrand factor-deficient mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] L. Cowan,et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. , 2000, Blood.
[41] Chediak,et al. Pharmacokinetics, efficacy and safety of Humate‐P® in von Willebrand disease , 1998 .
[42] K. Mohlke,et al. von Willebrand disease and quantitative variation in von Willebrand factor. , 1997, The Journal of laboratory and clinical medicine.
[43] E. Berntorp,et al. Pharmacokinetic dosing in prophylactic treatment of hemophilia A , 1993, European journal of haematology.
[44] K. Titani,et al. Human plasma alpha 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype. , 1993, Blood.
[45] W. Marks,et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. , 1987, Blood.
[46] J. Wear,et al. Experience with estramustine phosphate. , 1976, Wisconsin medical journal.